Premium
Expression of the multidrug‐resistance‐associated protein (MRP) gene in human colorectal, gastric and non‐small‐cell lung carcinomas
Author(s) -
Chuman Yutaka,
Sumizawa Tomoyuki,
Takebayashi Yuji,
Niwa Kiyoshi,
Yamada Kazutaka,
Haraguchi Misako,
Furukawa Tatsuhiko,
Akiyama Shinichi,
Aikou Takashi
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960410)66:2<274::aid-ijc23>3.0.co;2-b
Subject(s) - adenocarcinoma , multiple drug resistance , cell , lung , cancer research , gene expression , pathology , biology , epidermoid carcinoma , drug resistance , gene , cancer , carcinoma , medicine , biochemistry , genetics , microbiology and biotechnology
MRP has been identified as another multidrug‐resistance (MDR) gene and may be involved in an alternative MDR mechanism in some solid tumors. We investigated the expression of MRP mRNA in multidrug‐resistant KB sublines (KB‐8‐5, KB‐C2, C‐A40 and C‐A120), human non‐small‐cell lung carcinomas (NSCLC), gastric and colorectal carcinomas, and compared it with that in drug‐sensitive human KB cells, MRP gene expression was elevated in 8 of 9 (89%) squamous‐cell carcinomas of the lung. Furthermore, MRP expression in 4 squamous‐cell carcinomas (L13, 18, 19 and 20) was more than 3.6 times higher than in KB‐3‐I cells, and the average MRP mRNA expression level of all squamous‐cell carcinomas was significantly higher than that of adenocarcinoma of the lung and of colorectal and gastric carcinomas. These results suggested that the MRP is responsible, at least in part, for drug resistance in some squamous‐cell carcinomas of the lung. © 1996 Wiley‐Liss, Inc.